邁克生物(300463.SZ):子公司新產品獲得產品註冊證書
格隆匯 5 月 6日丨邁克生物(300463.SZ)公佈,公司全資子公司邁克醫療電子有限公司(“邁克醫療”)於近日收到四川省藥品監督管理局頒發的《醫療器械註冊證》。
此次獲得註冊證書的全自動特定蛋白分析儀P100(“P100”)為公司的新產品,其採用免疫散射比濁法對全血樣本進行分析,該產品可單機使用,也可與公司8系全自動血細胞分析儀、全自動糖化血紅蛋白分析儀聯機組成全自動血液分析工作站,實現一管血完成血常規、糖化、特定蛋白檢測,全面滿足實驗室自動化、多樣化檢驗需求,將進一步鞏固公司在血液檢測領域的競爭優勢。同時,公司綜合競爭力與市場拓展能力也將得到提升,對公司未來的經營將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.